Rhythm Pharmaceuticals Inc (RYTM) Stock Price, Quote & News

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 264 4280

Fax: 857 264 4299

Website: rhythmtx.com

Address:

222 Berkeley Street, 12th Floor, Boston, United States

Tumble51 Jul. 13 at 5:51 PM

$ALNY $CADL $RYTM Let’s get an instant replay on Cadl, shall we ? On the. 6 yard line 3rd down , Tak reverts to social media for the 1st down, with 4 yards to go for a 1st down … Cadl fcuks up again , ball on the $5 Haha No GOAT here, call Brady !! lol

3 · Reply

Night_Owl_Biotech Jul. 11 at 7:28 PM

$ZVRA is up 27% the last 2 weeks. We track all commercial-stage oncology & non-oncology focused bios via graphs like the one attached. ZVRA is the only subject bio in this peer group with a graph that reads like this the last 2 weeks (absent those with specific catalysts or inflections points like $VRNA $INSM & $RYTM). This is not investment advice because we do not follow ZVRA in any great detail. For all we know there was a specific ZVRA catalyst. Otherwise, this trading pattern is, at best, unusual or... $XBI

2 · Reply

Quantumup Jul. 11 at 5:39 PM

Goldman Sachs, on 7/10, resumed $RYTM Buy/$97 $SLNO $AARD LLY $VKTX $GPCR SRRK Goldman Sachs said in their note:

0 · Reply

Quantumup Jul. 11 at 1:29 PM

To be fair to the Goldman analyst, she did move to a Buy/$28 on $RYTM 1 month later, while stock was around $8, but the point is she writes a Very Bullish note on $TGTX, similar to $RYTM, but maybe forget to move to Buy and⬆️PT ? I don't know. I just see a Bullish $TGTX note, w/ a lot of info that points to a higher share price for $TGTX. I really should have added that in the post below, to be fair to her. She's a good analyst, imo.

0 · Reply

Tumble51 Jul. 11 at 12:37 PM

$ALNY $CADL $RYTM no objective of mine , another myth by begrudged shareholders against the truth, and in addition to TAK TALES told on social media by TAK , at $CADL !! Read below , the truth , of better run biotechs posted today ⬇️ Some CADL holders have the blinders on to the truth OR:

0 · Reply

Tumble51 Jul. 11 at 12:07 PM

$CADL ..knock yourself out !!! $CADL lacks the ability to create value. Petrie Dishes and trials don’t make winners Results do !!! $ALNY …read it and weep ($40 in 2021…$320 today ) $RYTM …read it and weep ($3 in 2022….$88 today ) WHY ????? credible and bright CEO’s at both !! NOT ON SOCIAL MEDIA with a pumping scenario Cadl $4 in 2023 …$6 today …POOR MGMT, POOR CEO Read the facts and weep CADL Lovers ….Big Money is elsewhere !!!! Not buying penny candy or Mary Jane’s DAH @FreedSage2013

2 · Reply

Quantumup Jul. 11 at 11:17 AM

Goldman Sachs, on 7/10, resumed $TGTX Neutral-$37. $RHHBY $NVS $BIIB SNY TEVA This report is "Very Bullish," for a Neutral-$37. Seems like this analyst made a mistake, the same type of mistake that she made on $RYTM July-2022, where I pointed to her Neutral/$6 PT, but her note was "Massively Bullish, and look at it now $94.8 high, Y'day. Anyway, GS said in its Note to investors:

1 · Reply

Quantumup Jul. 11 at 10:17 AM

Baird⬆️ $SLNO PT to $121 from $105, reiterated Outperform and said, "Positive on launch progress. $RYTM $ACAD $AARD $BIIB RHHBY Baird added, "Soleno's preliminary 2Q results feature impressive Vykat XR sales through the end of June of $31-$33M, in just the first 2.5 months following the mid-April launch. The guided range is well ahead of our/consensus expectations, and coupled with the formidable rate of new start forms, we have further strengthened confidence in Vykat's blockbuster potential. We are revising our price target to $121 accordingly."

1 · Reply

profitraider Jul. 10 at 9:06 PM

$RYTM this thing is going to sell off hard… careful Boyz!

1 · Reply

badprecog Jul. 10 at 8:32 PM

$RYTM So is this drug just for 20,000 patients, or can anyone take it potentially?

1 · Reply

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Jul 10, 2025, 3:39 PM EDT - 4 days ago

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Jul 10, 2025, 6:21 AM EDT - 5 days ago

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Jul 9, 2025, 4:16 PM EDT - 5 days ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jul 9, 2025, 8:00 AM EDT - 5 days ago

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Jul 8, 2025, 4:01 PM EDT - 6 days ago

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Jun 30, 2025, 11:00 AM EDT - 14 days ago

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Jun 25, 2025, 8:00 AM EDT - 19 days ago

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

May 14, 2025, 8:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 7, 2025, 3:21 PM EDT - 2 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

May 6, 2025, 8:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Apr 23, 2025, 8:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 8, 2025, 1:38 PM EDT - 3 months ago

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 7, 2025, 7:11 AM EDT - 3 months ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Apr 6, 2025, 12:00 PM EDT - 3 months ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Mar 31, 2025, 2:05 PM EDT - 3 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY VRTX XENE

Mar 20, 2025, 4:01 PM EDT - 4 months ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Mar 19, 2025, 4:01 PM EDT - 4 months ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Mar 18, 2025, 7:00 AM EDT - 4 months ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Feb 26, 2025, 1:46 PM EST - 4 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 4 months ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 25, 2025, 11:21 AM EST - 4 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 13, 2025, 8:00 AM EST - 5 months ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Jan 10, 2025, 7:15 AM EST - 6 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Dec 20, 2024, 2:24 PM EST - 7 months ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Dec 20, 2024, 2:15 PM EST - 7 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Dec 3, 2024, 6:00 AM EST - 8 months ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Nov 18, 2024, 7:00 AM EST - 8 months ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Nov 13, 2024, 6:30 PM EST - 8 months ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Nov 13, 2024, 4:01 PM EST - 8 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 5, 2024, 10:45 PM EST - 8 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 4:01 PM EST - 8 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Nov 4, 2024, 4:01 PM EST - 9 months ago

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Oct 24, 2024, 6:00 AM EDT - 9 months ago

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Sep 22, 2024, 7:36 AM EDT - 10 months ago

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Aug 29, 2024, 9:30 AM EDT - 11 months ago

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 26, 2024, 8:02 AM EDT - 11 months ago

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Aug 19, 2024, 1:49 PM EDT - 11 months ago

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

LLY SNY

Aug 6, 2024, 11:22 AM EDT - 1 year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 9:10 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Jul 23, 2024, 7:30 AM EDT - 1 year ago

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

Jun 3, 2024, 4:02 PM EDT - 1 year ago

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

Jun 3, 2024, 8:02 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference

May 22, 2024, 4:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

May 7, 2024, 9:50 PM EDT - 1 year ago

Rhythm Pharmaceuticals, Inc (RYTM) Q1 2024 Earnings Call Transcript

May 7, 2024, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update

Tumble51 Jul. 13 at 5:51 PM

3 · Reply

Night_Owl_Biotech Jul. 11 at 7:28 PM

2 · Reply

Quantumup Jul. 11 at 5:39 PM

Goldman Sachs, on 7/10, resumed $RYTM Buy/$97 $SLNO $AARD LLY $VKTX $GPCR SRRK Goldman Sachs said in their note:

0 · Reply

Quantumup Jul. 11 at 1:29 PM

0 · Reply

Tumble51 Jul. 11 at 12:37 PM

0 · Reply

Tumble51 Jul. 11 at 12:07 PM

2 · Reply

Quantumup Jul. 11 at 11:17 AM

1 · Reply

Quantumup Jul. 11 at 10:17 AM

1 · Reply

profitraider Jul. 10 at 9:06 PM

$RYTM this thing is going to sell off hard… careful Boyz!

1 · Reply

badprecog Jul. 10 at 8:32 PM

$RYTM So is this drug just for 20,000 patients, or can anyone take it potentially?

1 · Reply

IN0V8 Jul. 10 at 6:44 PM

$RYTM BofA Global Research ups price objective to $95 from $73 Morgan Stanley raises target to $95.00 from $80.00 Wells Fargo raises target price to $129 from $91

0 · Reply

anachartanalyst Jul. 10 at 6:02 PM

$RYTM https://anachart.com/wp-content/uploads/ana_temp/1752170541_soc-img.jpg

0 · Reply

Doozio Jul. 10 at 5:01 PM

$INCY that $ZYME is $NOW a Thursday 🐑 🎁 in $RYTM 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 10 at 4:34 PM

Out of da tightness MAMA said it comes in 3 $XBI shall $REPL da 🐑 as its already in $RYTM 🐒🍌🧠⏰♾️

0 · Reply

ZacksResearch Jul. 10 at 4:20 PM

$RYTM just ripped +36.6% — but is this just the beginning? Phase II data on bivamelagon showed strong reductions in BMI and hunger for acquired hypothalamic obesity patients — a big win for Rhythm. Full details on the data and what it could mean next 👉 https://www.zacks.com/stock/news/2571462/rytm-stock-rises-on-upbeat-acquired-hypothalamic-obesity-study-data?cid=sm-stocktwits-2-2571462-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2571462_TEASER

0 · Reply

SmallCapGrowth Jul. 10 at 3:13 PM

Hot Stock Alert: Volume Soars in $BCTX as the BIG News Rolls Out. Company reports complete & sustained resolution of brain metastasis and continued orbital tumor shrinkage in a breast cancer patient after 21 months on Bria-IMT Full details: https://globenewswire.com/news-release/2025/07/10/3113141/0/en/BriaCell-Reports-Complete-and-Sustained-Resolution-of-Brain-Metastasis-and-Sustained-Regression-of-Orbital-Metastasis-in-Eye-Bulging-Breast-Cancer-Patient.html $GAME $RYTM

0 · Reply

IN0V8 Jul. 10 at 3:07 PM

$RYTM 7/9/25 Baird raises target price to $95 from $72

0 · Reply

JarvisFlow Jul. 10 at 3:00 PM

Wells Fargo has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Overweight with a price target of 129.

0 · Reply

ZacksResearch Jul. 10 at 2:13 PM

$RYTM up 36.6% on positive Phase II results for bivamelagon! 🚀 The study showed significant BMI reductions and decreased hunger levels in patients with acquired hypothalamic obesity. Year to date, shares have surged 59% against the industry's decline. See the full study breakdown and what’s next for Rhythm Pharmaceuticals 👉 https://www.zacks.com/stock/news/2571462/rytm-stock-rises-on-upbeat-acquired-hypothalamic-obesity-study-data?cid=sm-stocktwits-2-2571462-body-1167&ADID=SYND_STOCKTWITS_TWEET_2_2571462_BODY_1167

0 · Reply

TeeMan123 Jul. 10 at 1:35 PM

$RYTM — Quick elaboration: current ~$5.5B market cap reflects HO/BBS only. There’s no value being ascribed to Prader-Willi yet. And we know Meeker — the GOAT doesn’t greenlight a trial unless he’s confident in efficacy. They've learned a lot about the drug, and he has strong conviction it’ll work in Prader. Meanwhile, $SLNO is a Prader-only story and it’s valued at ~$4.5B. By raising funds, Meeker is signaling he wants Prader priced into $RYTM. If the Phase 1 reads out positively by year-end, the stock could add $2–3B in value — taking it to ~$135/share.

0 · Reply

briefingcom Jul. 10 at 1:05 PM

$RYTM: Rhythm Pharmaceuticals priced of its upsized public offering of 2,058,824 shares of its common stock at a... https://www.briefing.com/in-depth-analysis/Content/Article?ArticleId=IN20250710062245RYTM&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

0 · Reply

OpenOutcrier Jul. 10 at 12:47 PM

$RYTM (-1.1% pre) Rhythm Pharmaceuticals prices $175M stock offering https://ooc.bz/l/69575

0 · Reply

Market Cap	5.52B
Revenue (ttm)	130.13M
Net Income (ttm)	-260.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-200.26%
Debt to Equity Ratio	0.00

Volume	736,600
Avg Vol	762,808
Day's Range	N/A - N/A
Shares Out	63.62M
Stochastic %K	82%
Beta	2.26
Analysts	Strong Sell
Price Target	$97.21